Pay in 4 interest-free payments of $5.30 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
QiLGaoRChenZLinDLiuZWangLet al
The Next GLP-1 Wave: How Oral Launches Could Accelerate Utilization and Risk GLP-1 agents have reshaped the management of obesity, and the market continues to accelerate as new agents and indications emerge
PlexusDx offers both Compounded Semaglutide Injection (at $189/mo month-to-month, or from $149/mo on the 6-month plan) and Compounded Tirzepatide Injection (at $289/mo month-to-month, or from $249/mo on the 6-month plan), allowing your provider to select the compound that matches your genetic risk profile
Long-term treatment of growth hormone insensitivity syndrome with IGF-I
Developed by Eli Lilly, retatrutide simultaneously targets GLP-1, GIP, and glucagon receptors, setting it apart from existing licensed treatments such as semaglutide and tirzepatide
US$ 21.93
US$ 20.72
US$ 24.83
US$ 27.52
US$ 23.45
